NTRK fusion-positive NSCLC: perspectives from pathology, oncology, and beyond
About the program
NTRK fusions are rare but actionable oncogenic drivers occurring in a small subset of NSCLC patients. With TRK inhibitors now available for patients with NTRK fusion-positive NSCLC, timely detection and evidence-based management are critical.
This expert-led, CME-accredited program delivers concise, practical education on NTRK fusion-positive NSCLC – spanning pathology, oncology, regulatory, and patient perspectives. Through a live webinar and enduring webcast, interactive patient case simulations, expert interviews (available as videos, podcasts, and articles), and downloadable clinical tools, you’ll gain actionable insights to improve care.
Learning objectives
Following completion of this independent educational program, you will be able to:
- Integrate appropriate methods for detecting molecular biomarkers in NSCLC, including rare alterations like NTRK fusions
- Evaluate efficacy and safety data supporting TRK inhibitors for NTRK fusion-positive NSCLC
- Implement shared decision-making strategies that reflect patient values and concerns
- Recognize barriers to accessing TRK inhibitors and explore strategies to improve treatment access
Target audience
This independent educational program is aimed at oncologists, pathologists, pulmonologists, nurses and nurse practitioners, and all other members of the multidisciplinary team managing NSCLC patients.
This program is aligned with Springer Medicine – an English-language, medical education platform provided by the Springer Nature Group. Springer Medicine supports doctors in their ongoing quest for optimal patient care, and delivers the latest evidence on new therapies, practice guidelines and news in easily digestible formats to keep healthcare professionals effortlessly up to date.